Where hidden drug capabilities come to light
Shadow BioSystems creates computational barcodes that capture the biological footprint of drugs and diseases. By representing both in the same physiological language, we can identify hidden therapeutic relationships, safety risks, and uncover opportunities for drug discovery and repurposing.
Drugs and diseases don't speak the same language.
We gave them one.
Drugs are described by targets, binding affinities, and adverse events. Diseases are described by symptoms, pathways, and molecular dysfunction.Shadow BioSystems projects both into a shared physiological coordinate space — built from adverse event data, target binding, tissue expression, and biological function.The distance between a drug's full biological footprint and its approved indication becomes a signal for repurposing, mechanism discovery, and therapeutic opportunity identification.398,528 drug-disease interactions barcoded, narrowed to 749 high-confidence repurposing candidates through a three-stage funnel: biological signal detection, novelty filtering against clinical trial history, and confidence classification.
83.2% approved-drug label recovery via blinded validation. 71x lift over random chance — no label leakage.67 disease areas with 100% label recovery — every currently approved drug for that disease, independently rediscovered by the platform.Recovery rate isn't uniform across diseases — and that variation is itself a signal. Diseases with well-annotated molecular targets show the strongest recovery; diseases with sparser target annotation show weaker recovery not because our biology is wrong, but because the underlying data is thinner. This segments our disease landscape into two zones: well-mapped diseases where the platform's precision is already validated, and an underdrugged frontier — diseases where target annotation is sparse today but where systematic barcoding is likely to reveal the most novel, uncontested therapeutic opportunity as annotation coverage grows.
Our Founder
Jonard Valdoz, Ph.D.Jon is the Founder and CEO of Shadow BioSystems and architect of its core algorithm.He previously led research and operations at a Silicon Valley deeptech startup developing translational 3D-printed lung models for preclinical drug development.Shadow BioSystems builds computational barcodes of drug and disease physiology to enable mechanism discovery and therapeutic prediction.
Let's talk
For investment, collaboration, or research partnerships.